Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DICER1-associated central nervous system sarcoma: A comprehensive clinical and genomic characterization of case series of young adult patients.
Cardona AF, Chamorro Ortiz DF, Ruíz-Patiño A, Gomez D, Muñoz Á, Ardila DV, Garcia-Robledo JE, Ordóñez-Reyes C, Sussmann L, Mosquera A, Forero Y, Rojas L, Hakim F, Jimenez E, Ramón JF, Cifuentes H, Pineda D, Mejía JA, Rodríguez J, Archila P, Sotelo C, Moreno-Pérez DA, Arrieta O. Cardona AF, et al. Among authors: arrieta o. Neurooncol Pract. 2023 Mar 19;10(4):381-390. doi: 10.1093/nop/npad014. eCollection 2023 Aug. Neurooncol Pract. 2023. PMID: 37457227 Free PMC article.
KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
Campos-Parra AD, Zuloaga C, Manríquez ME, Avilés A, Borbolla-Escoboza J, Cardona A, Meneses A, Arrieta O. Campos-Parra AD, et al. Among authors: arrieta o. Am J Clin Oncol. 2015 Feb;38(1):33-40. doi: 10.1097/COC.0b013e318287bb23. Am J Clin Oncol. 2015. PMID: 23538866
The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, Rodríguez J, Vargas C, Carranza H, Otero J, Karachaliou N, Astudillo H, Rosell R; CLICaP. Arrieta O, et al. Lung Cancer. 2015 Feb;87(2):169-75. doi: 10.1016/j.lungcan.2014.12.009. Epub 2014 Dec 18. Lung Cancer. 2015. PMID: 25558790
Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).
Arrieta O, Cardona AF, Martín C, Más-López L, Corrales-Rodríguez L, Bramuglia G, Castillo-Fernandez O, Meyerson M, Amieva-Rivera E, Campos-Parra AD, Carranza H, Gómez de la Torre JC, Powazniak Y, Aldaco-Sarvide F, Vargas C, Trigo M, Magallanes-Maciel M, Otero J, Sánchez-Reyes R, Cuello M. Arrieta O, et al. J Thorac Oncol. 2015 May;10(5):838-843. doi: 10.1097/JTO.0000000000000481. J Thorac Oncol. 2015. PMID: 25634006 Free article.
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Cuello M, Corrales L, Martín C, Ortiz C, Franco S, Rosell R; CLICaP. Cardona AF, et al. Among authors: arrieta o. PLoS One. 2016 May 18;11(5):e0154293. doi: 10.1371/journal.pone.0154293. eCollection 2016. PLoS One. 2016. PMID: 27191954 Free PMC article.
The safety of afatinib for the treatment of non-small cell lung cancer.
Barron F, de la Torre-Vallejo M, Luna-Palencia RL, Cardona AF, Arrieta O. Barron F, et al. Among authors: arrieta o. Expert Opin Drug Saf. 2016 Nov;15(11):1563-1572. doi: 10.1080/14740338.2016.1236910. Epub 2016 Sep 28. Expert Opin Drug Saf. 2016. PMID: 27633264 Review.
362 results